Milazzo S, Ernst E, Lejeune S, Schmidt K
Cochrane Database Syst Rev. 2006 Apr 19(2):CD005476. doi: 10.1002/14651858.CD005476.pub2.
Laetrile is an unconventional therapy which has been used illegally for decades by cancer patients who together with some alternative therapists claim its effectiveness as an anti-cancer treatment. It has been often referred to as amygdalin, although the two are not the same.
The aim of this review was to assess the alleged anti-cancer effect and the possible harms of Laetrile as a sole or adjunctive therapy in cancer treatment.
We searched The Cochrane Central Register of Controlled Trials (CENTRAL); MEDLINE (from 1951); EMBASE (from 1980); Allied and Complementary Medicine (AMED), Scirus, CancerLit, CINAHL (all from 1982); CAMbase (from 1998); the MetaRegister; the National Research Register and our own files. No language restrictions were imposed.
Randomized clinical trials (RCTs) and non randomized controlled clinical trials (non-RCTs).
Two reviewers independently assessed trials for inclusion in the review, assessed study quality and extracted data.
No RCTs or non-RCTs were found, so no abstraction of outcome data could be performed in this systematic review
AUTHORS' CONCLUSIONS: The claim that Laetrile has beneficial effects for cancer patients is not supported by data from controlled clinical trials. This systematic review has clearly identified the need for randomised or controlled clinical trials assessing the effectiveness of Laetrile or amygdalin for cancer treatment.
苦杏仁苷是一种非常规疗法，数十年来一直被癌症患者非法使用，这些患者与一些替代疗法治疗师一起声称其作为抗癌治疗方法具有有效性。它常被称为扁桃苷，尽管二者并不相同。
本综述的目的是评估苦杏仁苷作为癌症治疗的单一疗法或辅助疗法时所谓的抗癌效果及可能的危害。
我们检索了Cochrane对照试验中心注册库（CENTRAL）；MEDLINE（始于1951年）；EMBASE（始于1980年）；联合与补充医学数据库（AMED）、Scirus、CancerLit、护理学与健康照护数据库（CINAHL，均始于1982年）；CAMbase（始于1998年）；MetaRegister；国家研究注册库以及我们自己的资料库。未设语言限制。
随机临床试验（RCT）和非随机对照临床试验（非RCT）。
两名综述作者独立评估纳入综述的试验，评估研究质量并提取数据。
未发现随机临床试验或非随机对照临床试验，因此在本系统综述中无法提取结局数据。
苦杏仁苷对癌症患者有有益作用这一说法未得到对照临床试验数据的支持。本系统综述明确指出需要进行随机或对照临床试验来评估苦杏仁苷或扁桃苷对癌症治疗的有效性。
